FDA has announced its 2017 user fee rates related to the Generic Drug User Fee Program, which includes:
These fees are effective from October 1, 2016 through September 30, 2017. In its notice, FDA states that it expects to see an increase in the number of ANDA and PAS submissions that are received in 2017. As such, the 2017 fees for these types of submissions have decreased compared to the Agency’s 2016 fees. On the reverse side of that, FDA notes that the fees for DMF submissions have increased for 2017 compared to 2016, as it expects the number of these submissions to decrease next year. Additionally, the fees associated with all types of facilities will also increase in FY 2017. This is said to be due to a decrease in the number of facilities that have self-identified for fiscal year 2017.
FDA’s generic drug user fee rates for fiscal year 2017 are as follows:
Fee Category |
FY 2017 Fee Rates |
Applications: | |
Abbreviated New Drug Application (ANDA) | $70,480 |
Prior Approval Supplement (PAS) to an ANDA | $35,240 |
Drug Master File (DMF) | $51, 140 |
Facilities: | |
Active Pharmaceutical Ingredient (API) – Domestic | $44,234 |
API – Foreign | $59,234 |
Finished Dosage Form (FDF) – Domestic | $258,646 |
FDF – Foreign | $273,646 |
August 7, 2015
As required by the Generic Drug User Fee Amendments of 2012, FDA has announced the 2016 rates for the following user fees: Abbreviated new drug application (ANDA), Prior approval to an ANDA (PAS),...
August 7, 2018
On Friday, July 27th, FDA released a notice with updated generic drug user fee rates for fiscal year 2019. Under GDUFA II, user fees should total $493,600,000 each year, adjusted for inflation. The...
February 15, 2018
Throughout 2017, the FDA focused its attention on the regulation of generic drug products. In 2015, the Agency issued only two generic-related guidance documents. In 2016, there were seven. In...